ArticleFrontiers in aging neuroscience2024
Research on the application of functional near-infrared spectroscopy in differentiating subjective cognitive decline and mild cognitive impairment.
Article in Frontiers in aging neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic potential of near-infrared spectroscopy in mild cognitive impairment and neurodegenerative disorders: Implications for resource-limited settings.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- Cerebral activation following dynamic cycling in individuals with and without Parkinson's disease: an fNIRS investigation.Frontiers in human neuroscience · 2026Article
- An fNIRS-based investigation of cerebral hemodynamic responses during verbal fluency task and n-back task in individuals with mild cognitive impairment.Frontiers in neurology · 2025Article
- fNIRS-based early identification of mild cognitive impairment: a large-scale multi-paradigm study with ensemble machine learning models.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alzheimer's disease (AD) is a common neurological disorder. Based on clinical characteristics, it can be categorized into normal cognition (NC), subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia (AD). Once the condition begins to progress, the process is usually irreversible. Therefore, early identification and intervention are crucial for patients. This study aims to explore the sensitivity of fNIRS in distinguishing between SCD and MCI. Methods: An in-depth analysis of the Functional Connectivity (FC) and oxygenated hemoglobin (HbO) characteristics during resting state and different memory cognitive tasks is conducted on two patient groups to search for potential biomarkers. The 33 participants were divided into two groups: SCD and MCI. Results: Functional connectivity strength during the resting state and hemodynamic changes during the execution of Verbal Fluency Tasks (VFT) and MemTrax tasks were measured using fNIRS. The results showed that compared to individuals with MCI, patients with SCD exhibited higher average FC levels between different channels in the frontal lobe during resting state, with two channels' FC demonstrating significant ability to distinguish between SCD and MCI. During the VFT task, the overall average HbO concentration in the frontal lobe of SCD patients was higher than that of MCI patients from 5 experimental paradigm. Receiver operating characteristic analysis indicated that the accuracy of the above features in distinguishing SCD from MCI was 78.8%, 72.7%, 75.8%, and 66.7%, respectively. Discussion: fNIRS could potentially serve as a non-invasive biomarker for the early detection of dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.